Results 1 to 10 of about 252,954 (227)

Prospects for a MERS-CoV spike vaccine [PDF]

Expert Review of Vaccines, 2018
Introduction: Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012.
Yusen Zhou, Shibo Jiang, Lanying Du
exaly   +5 more sources

Development of Small-Molecule MERS-CoV Inhibitors

Viruses, 2018
Middle East respiratory syndrome coronavirus (MERS-CoV) with potential to cause global pandemics remains a threat to the public health, security, and economy. In this review, we focus on advances in the research and development of small-molecule MERS-CoV
Ruiying Liang, Naru Zhang, Tianlei Ying   +2 more
exaly   +4 more sources

MERS-CoV [PDF]

, 2019
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which ...
Du, Lanying, Li, Fang
core   +7 more sources

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Vaccine, 2017
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces
Christopher M Coleman, Thiagarajan Venkataraman, Gregory M Glenn   +2 more
exaly   +3 more sources

On-site detection of MERS-CoV infections in a camel slaughterhouse in Kenya using a commercial rapid antigen test [PDF]

Frontiers in Veterinary Science
BackgroundMiddle East respiratory syndrome coronavirus (MERS-CoV) poses a significant public health risk, with dromedary camels being the primary reservoir hosts.
Brian Maina Ogoti, Brian Maina Ogoti, Brian Maina Ogoti, Victor Riitho, Victor Riitho, Victor Riitho, Jordi Rodon, Nyamai Mutono, Nyamai Mutono, Nyamai Mutono, Julia Tesch, Julius Oyugi, Marianne W. Mureithi, Marianne W. Mureithi, Victor M. Corman, Victor M. Corman, Victor M. Corman, Christian Drosten, Christian Drosten, Christian Drosten, Johanna Wildemann, Samuel M. Thumbi, Samuel M. Thumbi, Samuel M. Thumbi, Samuel M. Thumbi, Marcel A. Müller, Marcel A. Müller   +26 more
doaj   +2 more sources

Colostrum from MERS-CoV seropositive camels for MERS prophylaxis and SARS-CoV-2 infection, a placebo controlled randomized trial [PDF]

Scientific Reports
COVID-19 pandemic is currently relatively controlled, mainly due to effective vaccines. Preparedness for future outbreaks should include means for reducing transmission of SARS-CoV-2 and other coronaviruses like MERS-CoV.
Hagit Masika, Meir Cherniak, Yelena Britan-Rosich, Yonatan Oster, Daniel Grupel, Ahmad Nama, Batel Nissan, David Planer, Jacob Strahilevitz, Eitan Israeli, Sujata Kumari, Orna Mor, Saveliy Kirillov, Joel Alter, Moshe Dessau, Jamal Fahoum, Einav Cohen-Kfir, Matan Golan, Reuven Wiener, Dan David, Reaan Amer, Alexander Rouvinski, Hila Elinav   +22 more
doaj   +2 more sources

Vaccines for the prevention against the threat of MERS-CoV [PDF]

Expert Review of Vaccines, 2016
First identified in 2012, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is listed as a new Category C Priority Pathogen. While the high mortality of MERS-CoV infection is further intensified by potential human-to-human transmissibility, no MERS vaccines are available for human use.
Lanying Du, Wanbo Tai, Yusen Zhou
exaly   +3 more sources

Immunogenicity and protective efficacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccines [PDF]

npj Viruses
While vaccines against Middle East respiratory syndrome coronavirus (MERS-CoV) have had substantial preclinical and clinical development, few vaccine candidates target other related viruses with potential for human spillover within the Merbecovirus ...
Peter J. Halfmann, Jeong Soo Lee, Tong Wang, Augustine Duffy, Yoshihiro Kawaoka, Ravi S. Kane   +5 more
doaj   +2 more sources

Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV [PDF]

Vaccines
Background. The pathogenic coronaviruses (CoVs) MERS-CoV and SARS-CoV-2, which are responsible for the MERS outbreak and the COVID-19 pandemic, respectively, continue to infect humans, with significant adverse outcomes.
Xiaoqing Guan, Abhishek K. Verma, Qian Liu, Melissa Palacios, Abby E. Odle, Stanley Perlman, Lanying Du   +6 more
doaj   +2 more sources

Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity

Vaccines, 2023
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a considerable threat to public health and global economies. SARS-CoV-2 has largely affected a vast world population and was declared a COVID-19 pandemic outbreak, with a substantial ...
Joud Mohammed AlKhalifah, Waleed Seddiq, Mohammed Abdullah Alshehri, Abdulkarim Alhetheel, Ahmed Albarrag, Sultan Ayoub Meo, Jaffar A. Al-Tawfiq, Mazin Barry   +7 more
doaj   +1 more source